Renal cathepsin G and angiotensin II generation

Journal of Hypertension

Volumn 24, Issue 9, 2006, Pages 1797-1807

  Rykl, Jana ^a   Thiemann, Joachim ^a   Kurzawski, Sandra ^a   Pohl, Thomas ^b   Gobom, Johan ^c   Zidek, Walter ^a   Schlüter, Hartmut ^a,d  

^a Internal Medicine Nephrology   (Germany)

^b WITA GmbH   (Germany)

^c MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiotensin II generating proteases; Cathepsin G; Mass spectrometry assisted enzyme screening; Protein identification; Protein purification; Renal tissue

Indexed keywords

ANGIOTENSIN II; ANTIPAIN; CATHEPSIN G; CHYMOSTATIN; HYDROXYAPATITE; LECTIN;

AFFINITY CHROMATOGRAPHY; ANALYTIC METHOD; ANIMAL TISSUE; ANION EXCHANGE; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; ELECTROPHORESIS; ELECTROSPRAY MASS SPECTROMETRY; ENZYME HISTOCHEMISTRY; ENZYME INHIBITION; ENZYME PURIFICATION; FRACTIONATION; GEL PERMEATION CHROMATOGRAPHY; ION TRAP MASS SPECTROMETRY; KIDNEY PARENCHYMA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MASS SPECTROMETRY ASSISTED ENZYME SCREENING SYSTEM; MATRIX ASSISTED LASER DESORPTION IONIZATION MASS FINGERPRINT ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; ONE DIMENSIONAL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; SWINE; TWO DIMENSIONAL ELECTROPHORESIS;

EID: 33747382786     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000242404.91332.be     Document Type: Article

References (43)

1. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273:1450-1456.
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
3. Ramaha A, Patston PA. Release and degradation of angiotensin I and angiotensin II from angiotensinogen by neutrophil serine proteinases. Arch Biochem Biophys 2002; 397:77-83.
4. Ishizuka Y, Shoda A, Yoshida S, Kawamura Y, Haraguchi K, Murakami K. Isolation and characterization of recombinant human prorenin in Chinese hamster ovary cells. J Biochem 1991; 109:30-35.
5. Sasaguri M, Ideishi M, Ogata S, Miura S, Ikeda M, Arakawa K. Human urinary kallikrein can generate angiotensin II from homologous renin substrates. Hypertens Res 1995; 18:33-37.
6. Hu WY, Fukuda N, Ikeda Y, Suzuki R, Tahira Y, Takagi H, et al. Human-derived vascular smooth muscle cells produce angiotensin II by changing to the synthetic phenotype. J Cell Physiol 2003; 196:284-292.
7. Jaspard E, Alhenc-Gelas F. Catalytic properties of the two active sites of angiotensin I-converting enzyme on the cell surface. Biochem Biophys Res Commun 1995; 211:528-534.
8. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277:14838-14843.
9. Jackman HL, Massad MG, Sekosan M, Tan F, Brovkovych V, Marcic BM, Erdos EG. Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension 2002; 39:976-981.
10. Muilenburg DJ, Raymond WW, Wolters PJ, Caughey GH. Lys40 but not Arg143 influences selectivity of angiotensin conversion by human alpha-chymase. Biochim Biophys Acta 2002; 1596:346-356.
11. Owen CA, Campbell EJ. Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. J Immunol 1998; 160:1436-1443.
12. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 2004; 383:45-51.
13. Moreau T, Brillard-Bourdet M, Bouhnik J, Gauthier F. Protein products of the rat kallikrein gene family. Substrate specificities of kallikrein rK2 (tonin) and kallikrein rK9. J Biol Chem 1992; 267:10045-10051.
14. Singh R, Singh AK, Leehey DJ. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol 2005; 288:F1183-F1190.
15. Genest J, Cantin M, Garcia R, Thibault G, Gutkowska J, Schiffrin E, et al. Extrarenal angiotensin-forming enzymes. Clin Exp Hypertens A 1983; 5:1065-1080.
16. Wintroub BU, Klickstein LB, Watt KW. A human neutrophil-dependent pathway for generation of angiotensin II. Purification of the product and identification as angiotensin II. J Clin Invest 1981; 68:484-490.
17. Urata H, Nishimura H, Ganten D. Chymase-dependent angiotensin II forming system in humans. Am J Hypertens 1996; 9:277-284.
18. Liao Y, Husain A. The chymase-angiotensin system in humans: Biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995; 11:13F-19F.
19. Urata H, Kinoshita A, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265:22348-22357.
20. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 1993; 43:1-20.
21. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417:822-828.
22. Schlüter H, Jankowski J, Rykl J, Thiemann J, Belgardt S, Zidek W, et al. Detection of protease activities with the mass-spectrometry-assisted enzyme-screening (MES) system. Anal Bioanal Chem 2003; 377:1102-1107.
23. Thiemann T, Jankowski J, Rykl J, Kurzawski S, Pohl T, Wittmann-Liebold B, Schluter H. Principle and applications of the protein-purification-parameter screening system. J Chromatogr A 2004; 1043:73-80.
24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248.
25. WITA. 2D Electrophoresis large scale format, user's manual. Teltow: WITA. [website: www.wita.de].
26. Klose J, Kobalz U. Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome. Electrophoresis 1995; 16:1034-1059.
27. Jensen ON, Wilm M, Shevchenko A, Mann M. Proteome analysis protocols. In: Link A, editor. 2-D proteome analysis protocols. Methods in Molecular Biology Series, vol. 112. Totowa, NJ: Humana Press; 1999. pp. 513-530.
28. Gobom J, Mueller M, Egelhofer V, Theiss D, Lehrach H, Nordhoff E. A calibration method that simplifies and improves accurate determination of peptide molecular masses by MALDI-TOF MS. Anal Chem 2002; 74:3915-3923.
29. Klickstein LB, Kaempfer CE, Wintroub BU. The granulocyte-angiotensin system. Angiotensin I-converting activity of cathepsin G. J Biol Chem 1982; 257:15042-15046.
30. Campbell EJ, Silverman EK, Campbell MA. Elastase and cathepsin G of human monocytes: quantification of cellular content, release in response to stimuli, and heterogeneity in elastase-mediated proteolytic activity. J Immunol 1989; 143:2961-2968.
31. Kargi HA, Campbell EJ, Kuhn C. Elastase and cathepsin G of human monocytes: heterogeneity and subcellular localization to peroxidase-positive granules. J Histochem Cytochem 1990; 38:1179-1186.
32. Heck LW, Rostand KS, Hunter FA, Bhown A. Isolation, characterization, and amino-terminal amino acid sequence analysis of human neutrophil cathepsin G from normal donors. Anal Biochem 1986; 158:217-227.
33. Klickstein LB, Kaempfer CE, Wintroub BU. The granulocyte angiotensin system. J Biol Chem 1982; 257:15042-15046.
34. Twumasi DY, Liener IE. Proteases from purulent sputum: purification and properties of the elastase and chymotrypsin-like enzymes. J Biol Chem 1977; 252:1917.
35. Bjork P, Luts A, Sundler F, Ohlsson K. Turnover and distribution of cathepsin G in the rat. Scand J Clin Lab Invest 1993; 53:539-546.
36. Nie J, Pei D. Rapid inactivation of alpha-1-proteinase inhibitor by neutrophil specific leukolysin/membrane-type matrix metalloproteinase 6. Exp Cell Res 2004; 296:145-150.
37. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, et al. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A 2002; 99:4465-4470.
38. Uhlen M, Ponten F. Antibody-based proteomics for human tissue profiling. Mol Cell Proteomics 2005; 4:384-393.
39. Wright CD, Kennedy JA, Zitnik RJ, Kashem MA. Inhibition of murine neutrophil serine proteinases by human and murine secretory leukocyte protease inhibitor. Biochem Biophys Res Commun 1999; 254:614-617.
40. Ohlsson S, Ljungkrantz I, Ohlsson K, Segelmark M, Wieslander J. Novel distribution of the secretory leucocyte proteinase inhibitor in kidney. Mediators Inflamm 2001; 10:347-350.
41. Bjork P, Luts A, Sundler F, Ohlsson K. Turnover and distribution of cathepsin G in the rat. Scand J Clin Lab Invest 1993; 53:539-546.
42. Wiedow O, Meyer-Hoffert U. Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. J Intern Med 2005; 257:319-328.
43. Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 2005; 11:RA155-RA162.